Cash Flow Statement (Annual)
ADMA / ADMA Biologics Inc Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities|
|Net Income Loss||-5,903||-7,301||-15,527||-16,813||-17,970||-19,515||-43,759|
|Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Depreciation And Amortization||220||182||211||248||470||470||2,692|
|Gain Loss On Disposition Of Assets||-1||-18||-||-||-||0||-10|
|Share Based Compensation||23||627||888||1,248||1,711||1,250||1,562|
|Amortization Of Debt Discount Premium||741||3||92||133||354||677||782|
|Amortization Of License Revenue||-||0||-44||-76||-127||-143||-143|
|Increase Decrease In Operating Capital|
|Increase Decrease In Accounts Receivable||0||-39||39||384||541||94||2,862|
|Increase Decrease In Inventories||-308||118||403||40||1,737||1,574||-589|
|Increase Decrease In Prepaid Expense||-6||49||191||-155||-33||203||941|
|Increase Decrease In Other Operating Assets||-||-115||593||15||0||0||483|
|Increase Decrease In Accounts Payable||40||-245||1,609||-938||309||477||2,812|
|Increase Decrease In Accrued Liabilities||285||151||76||1,352||-200||417||614|
|Increase Decrease In Other Current Liabilities||-||-||-||-||-||-31||-12|
|Net Cash Provided By Used In Operating Activities||-1,431||-6,904||-10,887||-14,705||-15,418||-18,269||-37,272|
|Net Cash Provided By Used In Investing Activities|
|Proceeds From Sale Of Short Term Investments||-||-||-||-||-||-||-|
|Payments To Acquire Property Plant And Equipment||0||119||197||2,323||26||73||2,676|
|Cash Acquired From Acquisition||-||-||-||-||-||0||12,500|
|Net Cash Provided By Used In Investing Activities||-0||-119||-3,132||-4,041||-1,742||905||15,214|
|Net Cash Provided By Used In Financing Activities|
|Repayments Of Notes Payable||200||200||-||0||15,301||0||20,000|
|Proceeds From Issuance Or Sale Of Equity||-||-||-||-||-||-||-|
|Proceeds From Issuance Of Debt||-||-||-||-||-||0||15,000|
|Payments Of Debt Issuance Costs||-||25||-||30||228||47||1,650|
|Repayments Of Long Term Capital Lease Obligations||-||-||-||-||-||-||-|
|Repayments Of Debt And Capital Lease Obligations||10||10||12||13||14||15||17|
|Net Cash Provided By Used In Financing Activities||1,290||19,471||27,633||9,795||10,402||16,838||60,751|
|Cash And Cash Equivalents Period Increase Decrease||-141||12,448||13,614||-8,950||-6,758||-526||38,693|
Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)
ARIA / ARIAD Pharmaceuticals, Inc.
AVIR / Aviragen Therapeutics, Inc.
AVXS / AveXis, Inc.
BOTA / Biota Pharmaceuticals, Inc.
CASI / CASI Pharmaceuticals, Inc.
CYTR / CytRx Corp.
EIGR / Eiger BioPharmaceuticals, Inc.
FENC / Fennec Pharmaceuticals Inc.
GNMC / Aevi Genomic Medicine, Inc.
Related News Stories
Today we will revisit ADMA Biologics, a small biotech whose stock has rallied recently to nearly $7.00 a share. (0-1)
ADMA Biologics shares are already up 10% in less than a week since the trade was mentioned to subscribers of the premium Marketplace service. Shares have more upside ahead.
ADMA Biologics recently announced that the FDA had set an October 25, 2018, PDUFA Date for Bivigam.
Discussion: ADMA Biologics (ADMA) announced that its request for amendment to BLA to relaunch BIVIGAM (intravenous immune globulin [human], 10%). PDUFA is on October 25. If the BLA is successful the product is expected to be launched in Q1 2019. Shares moved up 18% on this positive news. Following earlier FDA letters in 2014 and 2016 warning of the production facility of the drug, IVIG manufacturing facility was earlier shut down. (3-0)
ADMA is in the third inning of a corporate turn-around. A manufacturing-related Warning Letter is preventing ADMA from reintroducing Bivigam to the market ($60m Revs/yr) and getting FDA approval for RI-002 (could be a $200m+/yr). While ADMA management has stated that their facility is inspection-ready, there has been a lot of uncertainty about the timing of the required FDA re-inspection and about the success of ADMA's efforts to fix the manufacturing issues. (5-5)
Using a set of 3 criterion, we have singled out MEI Pharma's offering for an analysis. (169-14)
as of ET